Abstracts
PIN2 ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV) LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
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3 University of Southern California, Los Angeles, CA, USA OBJECTIVES: To evaluate the cost effectiveness of entecavir in reducing HBV DNA viral load(VL) and subsequent compensated cirrhosis (CC), decompensate cirrhosis (DC), and hepatocellular cancer(HCC). METHODS: The analytic perspective was that of a third-party payer. We used patient-level drug exposure and VL data from a randomized phase III trial of 715 HBeAg+ CHB patients, and estimates of cost offsets and life expectancy gains as a result of the prevention of projected clinical events. The multivariate-adjusted relative risks with VL categories were estimated by Cox proportional hazards models from a Taiwan cohort of 3851 CHB subjects with 42,115 person-years of follow-up, and then applied to the trial patients whose VL were measured at Week 48 to estimate event risks. Entecavir and lamivudine were assigned daily prices of $19.43 and $6.14 respectively, based on recent First Data-Bank reports. Life expectancy for DC and HCC was estimated by the declining exponential approximation of life expectancy (DEALE) method. Other model parameter values were derived from external sources. The uncertainty surrounding event distribution and treatment failure rates beyond trial period were considered using probabilistic sensitivity analyses (PSA) with 1000 replicates. RESULTS: Subjects were male (75%), Asian (57%) or white (40%) with mean age 35 years. Entecavir was superior to lamivudine for the proportion of subjects who achieved HBV DNA < 300 copies/ml by PCR assay at Week 48 (67% versus 37% , respectively) (P < 0.05). One year of entecavir therapy gained 0.7843 quality-adjusted life year (QALY) at an incremental cost of $1607, with a 3% annual discount. Compared with lamivudine, using entecavir cost an incremental $2049 per QALY gained (95%CI: $688, $5134), with 98.8% of PSAderived estimates below $10,000/QALY. Results are robust and most sensitive to treatment duration, efficacy, and cost. CON-CLUSIONS: Entecavir given for one year is clinically effective and highly cost-effective in HBeAg+ patients. 3 Hoffmann-La Roche, Nutley, NJ, USA OBJECTIVE: To establish the clinical prognosis, costs and costeffectiveness of peginterferon alfa-2a (180 mcg/week) plus ribavirin versus no treatment in patients with CHC and PNALT from a Spanish national health care system (NHS) perspective. METHODS: A Markov model was developed to simulate the disease progression of 45-year old patients with CHC and PNALT. Fibrosis progression rates in PNALT were obtained from published studies. Efficacy, in terms of sustained virological response (SVR), for peginterferon alfa-2a plus ribavirin and no treatment in patients with genotype 1 and genotype 2/3 was obtained from a multinational, randomized, controlled trial. In this trial, no patients in the control arm achieved an SVR. Transition probabilities and quality of life estimates were obtained from published literature. Unit costs were obtained from a Spanish database. The discount rate employed was 3.5%. RESULTS: In genotype 1 patients, peginterferon alfa-2a plus ribavirin compared with no treatment increases patients life expectancy by 0.63 years (0.70 quality-adjusted life years (QALYs)), yielding an incremental cost-effectiveness ratio (ICER) of 14,729 €/ life year gained (LYG) (€13,388/QALY). In genotype 2/3 patients, peginterferon alfa-2a plus ribavirn increases life expectancy by 1.14 years (1.26 QALYs), yielding an ICER of 109 €/LYG (99 €/QALY). The overall ICER based on the genotype distribution in the trial is €11,374/LYG (€9952/QALY). CONCLUSIONS: From the Spanish NHS perspective, peginterferon alfa-2ª (40 KD) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with CHC and PNALT is a cost-effective treatment option, regardless of HCV genotype. 3 Summa Health System, Akron, OH, USA; 4 Bayer Health care AG, Wuppertal, Germany OBJECTIVE: To evaluate the cost-effectiveness of the empirical use of moxifloxacin in community-acquired pneumonia (CAP) taking into account clinical failure caused by prevailing levels of antimicrobial resistance in France, Germany and the US representing high, low and moderate levels of resistance respectively. METHODS: Only anecdotal evidence is available in the literature on the direct link between resistance and clinical failure. A decision analytic model was developed to estimate clinical failure by studying the resistance mechanisms of three common CAP pathogens, S.pneumoniae, H.influenzae and the atypical pathogens. It was estimated that in most cases 95% of resistant pathogens would result in clinical failure. Country-specific resistance rates for moxifloxacin, macrolides, beta-lactams and doxycycline were obtained from surveillance studies. Multi-drug resistance was estimated using US multi-drug resistance rates. Treatment algorithms were partially based on CAP treatment guidelines for out-patients of the Fine risk categories, I to III, focusing on mono-therapy. Patients could receive up to two treatments in the community and one hospitalisation. The outcomes evaluated were clinical failure avoided, hospitalisations avoided and second-line treatments avoided. Resource use and costs were obtained from the literature. Expert opinion was used extensively to validate the clinical assumptions. RESULTS: Moxifloxacin dominated all other treatments in France and the US and roxithromycin and cefuroxim strategies in Germany. Clinical failure rates for moxifloxacin and macrolide strategies were 5.3% and 47.3% in France, 5.2% and 16.8% in Germany and 5.2% and 23.6% the US respectively. In Germany compared to a strategy of amoxicillin followed by roxithromycin, moxifloxacin had an incremental cost-effectiveness of €1 per clinical failure avoided, but prevented 9646 clinical failures and 918 hospitalisations per 100,000 patients. CONCLUSIONS: Antimicrobial resistance has a significant impact on the costeffectiveness of empirical treatment of CAP. The first-line use of moxifloxacin in CAP is a cost-effective strategy for all levels of resistance. University of Groningen, Groningen, Groningen, The Netherlands; 2 Foundation for STI Control, Amsterdam, Noord Holland, The Netherlands OBJECTIVES: To estimate the cost-effectiveness of a systematic Chlamydia trachomatis (CT) screening program including partner treatment for The Netherlands using a dynamic approach. METHODS: Data on infection prevalence, participation rates and sexual behaviour were obtained from a large pilot study conducted in The Netherlands. We developed a dynamic SIS (Susceptible-Infected-Susceptible) model, which is widely used in exploring the transmission dynamics of infectious diseases, to estimate the impact of screening men and women on the incidence and prevalence of CT in the population. Subsequently, a progression-of-disease tree was used to calculate the complications averted by the screening program. Cost-effectiveness is expressed as the net costs per major outcome averted (MOA). We compared doing nothing both with a one-off screening program and with screening on various time intervals. RESULTS: Compared to do-nothing the one-off screening program is estimated to cost €373 per MOA. However, restricting the screening to women only the program is estimated to save costs. Even though screening on various time intervals adverts more serious complications, this is less cost effective as the screening related costs increase relatively more (e.g. bi-annual screening is estimated to cost €3200 per MOA compared to donothing). CONCLUSION: Our cost-effectiveness analysis shows that society has net to pay for the prevention of CT complications. A one-off screening program is however more costeffective than screening on various time intervals. One could argue that €373 per MOA, for the one-off screening program, is an acceptable cost-effectiveness. A screening program consisting of screening women only should always be adopted from a pharmacoeconomic point of view.
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